WO2005009958A1 - Ppar active compounds - Google Patents

Ppar active compounds Download PDF

Info

Publication number
WO2005009958A1
WO2005009958A1 PCT/US2004/023234 US2004023234W WO2005009958A1 WO 2005009958 A1 WO2005009958 A1 WO 2005009958A1 US 2004023234 W US2004023234 W US 2004023234W WO 2005009958 A1 WO2005009958 A1 WO 2005009958A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
compound
binding
ppar
heteroaryb
Prior art date
Application number
PCT/US2004/023234
Other languages
English (en)
French (fr)
Inventor
James Arnold
Dean R. Artis
Clarence Hurt
Prabha N. Ibrahim
Heike Krupka
Jack Lin
Michael V. Milburn
Weiru Wang
Chao Zhang
Original Assignee
Plexxikon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ545326A priority Critical patent/NZ545326A/en
Priority to AU2004259738A priority patent/AU2004259738B2/en
Application filed by Plexxikon, Inc. filed Critical Plexxikon, Inc.
Priority to KR1020137002335A priority patent/KR20130023381A/ko
Priority to CA002532403A priority patent/CA2532403A1/en
Priority to DK04778641.3T priority patent/DK1648867T3/da
Priority to SI200432116T priority patent/SI1648867T1/sl
Priority to UAA200600453A priority patent/UA88767C2/uk
Priority to BRPI0412684-0A priority patent/BRPI0412684A/pt
Priority to KR1020067001015A priority patent/KR101415503B1/ko
Priority to EP04778641.3A priority patent/EP1648867B1/en
Priority to JP2006520413A priority patent/JP4845730B2/ja
Publication of WO2005009958A1 publication Critical patent/WO2005009958A1/en
Priority to IL173079A priority patent/IL173079A/en
Priority to EC6288A priority patent/ECSP066288A/es
Priority to NO20060385A priority patent/NO20060385L/no
Priority to HK06108153.0A priority patent/HK1086010A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
PCT/US2004/023234 2003-07-17 2004-07-16 Ppar active compounds WO2005009958A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
KR1020067001015A KR101415503B1 (ko) 2003-07-17 2004-07-16 Ｐｐａｒ 활성 화합물
BRPI0412684-0A BRPI0412684A (pt) 2003-07-17 2004-07-16 compostos ppar-ativos
KR1020137002335A KR20130023381A (ko) 2003-07-17 2004-07-16 Ｐｐａｒ 활성 화합물
AU2004259738A AU2004259738B2 (en) 2003-07-17 2004-07-16 PPAR active compounds
DK04778641.3T DK1648867T3 (da) 2003-07-17 2004-07-16 Ppar-aktive forbindelser
SI200432116T SI1648867T1 (sl) 2003-07-17 2004-07-16 Ppar aktivne spojine
EP04778641.3A EP1648867B1 (en) 2003-07-17 2004-07-16 Ppar active compounds
NZ545326A NZ545326A (en) 2003-07-17 2004-07-16 PPAR active compounds
CA002532403A CA2532403A1 (en) 2003-07-17 2004-07-16 Ppar active compounds
UAA200600453A UA88767C2 (uk) 2003-07-17 2004-07-16 Ppar активні сполуки
JP2006520413A JP4845730B2 (ja) 2003-07-17 2004-07-16 Ｐｐａｒ活性化合物
IL173079A IL173079A (en) 2003-07-17 2006-01-11 Ppar active compounds, pharmaceutical compositions comprising them and uses thereof for preparing medicaments
EC6288A ECSP066288A (es) 2003-07-17 2006-01-16 Compuestos activos de ppar
NO20060385A NO20060385L (no) 2003-07-17 2006-01-24 Ppar-Aktive forbindelser
HK06108153.0A HK1086010A1 (en) 2003-07-17 2006-07-21 Ppar active compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48852303P 2003-07-17 2003-07-17
US60/488,523 2003-07-17
US55299404P 2004-03-12 2004-03-12
US60/552,994 2004-03-12

Publications (1)

Publication Number Publication Date
WO2005009958A1 true WO2005009958A1 (en) 2005-02-03

Family

ID=34107772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/023234 WO2005009958A1 (en) 2003-07-17 2004-07-16 Ppar active compounds

Country Status (18)

Country Link
US (5) US7202266B2 (US07476746-20090113-C00218.png)
EP (1) EP1648867B1 (US07476746-20090113-C00218.png)
JP (1) JP4845730B2 (US07476746-20090113-C00218.png)
KR (2) KR20130023381A (US07476746-20090113-C00218.png)
CN (1) CN102875441A (US07476746-20090113-C00218.png)
AU (1) AU2004259738B2 (US07476746-20090113-C00218.png)
BR (1) BRPI0412684A (US07476746-20090113-C00218.png)
CA (1) CA2532403A1 (US07476746-20090113-C00218.png)
CR (1) CR8194A (US07476746-20090113-C00218.png)
DK (1) DK1648867T3 (US07476746-20090113-C00218.png)
EC (1) ECSP066288A (US07476746-20090113-C00218.png)
HK (1) HK1086010A1 (US07476746-20090113-C00218.png)
IL (1) IL173079A (US07476746-20090113-C00218.png)
NO (1) NO20060385L (US07476746-20090113-C00218.png)
NZ (1) NZ545326A (US07476746-20090113-C00218.png)
RU (1) RU2356889C2 (US07476746-20090113-C00218.png)
UA (1) UA88767C2 (US07476746-20090113-C00218.png)
WO (1) WO2005009958A1 (US07476746-20090113-C00218.png)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002125A1 (en) * 2004-06-23 2006-01-05 Wyeth Indolylalkylamine metabolites as 5-hydroxytrytamine-6 ligands
FR2890071A1 (fr) * 2005-08-30 2007-03-02 Fournier Sa Sa Lab Nouveaux composes de l'indole
WO2007026104A1 (fr) * 2005-09-01 2007-03-08 Laboratoires Fournier S.A. Derives de pyrrolopyridine et leurs utilisations comme modulateurs des recepteurs ppar
WO2007030559A2 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1, 3-disubstituted indole derivatives for use as ppar modulators
WO2008109700A1 (en) * 2007-03-08 2008-09-12 Plexxikon, Inc. Ppar active compounds
US7476746B2 (en) 2003-07-17 2009-01-13 Plexxikon, Inc. PPAR active compounds
US7531568B2 (en) 2004-11-30 2009-05-12 Plexxikon, Inc. PPAR active compounds
US7572806B2 (en) 2003-07-17 2009-08-11 Plexxikon, Inc. PPAR active compounds
WO2009111279A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Pyrazole [3, 4-b] pyridine raf inhibitors
WO2010106076A1 (fr) 2009-03-16 2010-09-23 Laboratoires Arkopharma STIMULATEUR MÉTABOLIQUE DES PPARs À BASE D'ESTERS D'ACIDES GRAS LIBRES INSATURÉS, COMPOSITION HUILEUSE ET COMPLÉMENT ALIMENTAIRE LES CONTENANT
US7842692B2 (en) * 2005-07-22 2010-11-30 Shionogi & Co., Ltd. Azaindole derivative having PGD2 receptor antagonistic activity
US7855225B2 (en) 2006-03-02 2010-12-21 Astellas Pharma Inc. 17βHSD type 5 inhibitor
WO2010127264A3 (en) * 2009-04-30 2010-12-23 Burnham Institute For Medical Research HNF4α ANTAGONISTS AND METHODS OF USE
WO2010127246A3 (en) * 2009-04-30 2010-12-29 Burnham Institute For Medical Research Hnf4 modulators and methods of use
WO2011083278A1 (fr) 2010-01-08 2011-07-14 Laboratoires Fournier Sa Nouveaux derives de type pyrrolopyridine benzoique
WO2011086307A1 (fr) 2010-01-08 2011-07-21 Laboratoires Fournier S.A. Dérivés de pyrrolopyridine comme activateurs de nurr-1 utiles pour le traitement de la maladie de parkinson
WO2012178142A1 (en) * 2011-06-23 2012-12-27 Metabolic Solutions Development Company, Llc Ppar-sparing compounds and combinations fort the treatment of diabetes and other metabolic diseases
US8420666B2 (en) 2007-03-14 2013-04-16 Ranbaxy Laboratories Limited Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors
WO2013169864A2 (en) 2012-05-08 2013-11-14 Lycera Corporation TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
WO2015050412A1 (en) * 2013-10-02 2015-04-09 Daewoong Pharmaceutical Co., Ltd. Sulfonylindole derivatives and method for preparing the same
WO2018033455A1 (de) 2016-08-15 2018-02-22 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
US11738004B2 (en) 2011-10-17 2023-08-29 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005017106A2 (en) * 2003-06-17 2005-02-24 California Institute Of Technology Libraries of optimized cytochrome p450 enzymes and the optimized p450 enzymes
WO2005026193A2 (en) * 2003-09-08 2005-03-24 United States Army Medical Research And Materiel Command Small molecules and a pharmacophore model for inhibition of botulinum toxin and methods of making and using thereof
EP1833787A2 (en) * 2004-11-30 2007-09-19 Plexxikon, Inc. Indole derivatives for use as ppar active compounds
US20080234349A1 (en) * 2005-09-07 2008-09-25 Jack Lin PPAR active compounds
AU2006287521A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. PPARactive compounds
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
EP2170830B1 (en) 2007-07-17 2014-10-15 Plexxikon, Inc. 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
ES2627911T3 (es) 2009-11-18 2017-08-01 Plexxikon, Inc. Derivados de N-[2-fluoro-3-(4-amino-7H-pirrolo[2,3-d]pirimidin-5-carbonil)-fenil]-4-bencenosulfonamida como moduladores de la proteína quinasa Raf para el tratamiento del cáncer
AU2010336524B2 (en) 2009-12-23 2015-10-08 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
ES2652363T3 (es) 2010-08-18 2018-02-01 Samumed, Llc Dicetonas e hidroxicetonas como activadores de la vía de señalización de catenina
TR201816421T4 (tr) 2011-02-07 2018-11-21 Plexxikon Inc Kinaz modülasyonu için bileşikler ve metotlar ve bunların endikasyonları.
AU2012255275B2 (en) 2011-05-17 2016-01-28 Plexxikon Inc. Kinase modulation and indications therefor
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US10227357B2 (en) 2012-09-06 2019-03-12 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
KR102212923B1 (ko) 2012-12-21 2021-02-04 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
RU2680716C2 (ru) 2013-02-22 2019-02-26 СЭМЬЮМЕД, ЭлЭлСи γ-ДИКЕТОНЫ В КАЧЕСТВЕ АКТИВАТОРОВ WNT/β-КАТЕНИНОВОГО СИГНАЛЬНОГО ПУТИ
KR102244719B1 (ko) 2013-03-15 2021-04-26 플렉시콘 인코퍼레이티드 헤테로시클릭 화합물 및 그의 용도
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
SG11201509338QA (en) 2013-05-30 2015-12-30 Plexxikon Inc Compounds for kinase modulation, and indications therefor
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3142652B1 (en) 2014-05-14 2021-08-25 The Regents of the University of Colorado, a body corporate Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
EP3206686B1 (en) 2014-08-20 2019-10-09 Samumed, LLC Gamma-diketones for treatment and prevention of aging skin and wrinkles
EP3194392B1 (en) 2014-09-15 2020-01-01 Plexxikon, Inc. Heterocyclic compounds and uses thereof
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9802932B2 (en) 2015-05-06 2017-10-31 Plexxikon Inc. Solid forms of a compound modulating kinases
HUE047657T2 (hu) 2015-05-06 2020-05-28 Plexxikon Inc Kináz-moduláló hatású 1H-pirrolo[2,3-b]piridin származékok szintézise
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
KR20180052757A (ko) 2015-09-21 2018-05-18 플렉시콘 인코퍼레이티드 헤테로시클릭 화합물 및 그의 용도
ITUB20153978A1 (it) * 2015-09-28 2017-03-28 Laboratorio Chimico Int S P A Procedimento per la preparazione di derivati di indanammina e di nuovi intermedi di sintesi.
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3430005B1 (en) 2016-03-16 2021-12-08 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
CA3047580A1 (en) 2016-12-23 2018-07-26 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
US10577366B2 (en) 2017-03-20 2020-03-03 Plexxikon Inc. Crystalline forms of a compound that inhibits bromodomain
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
US10435404B2 (en) 2017-07-25 2019-10-08 Plexxikon Inc. Formulations of a compound modulating kinases
WO2019075243A1 (en) 2017-10-13 2019-04-18 Plexxikon Inc. SOLID FORMS OF A COMPOUND FOR MODULATING KINASES
CA3080197C (en) 2017-10-27 2023-12-19 Plexxikon Inc. Formulations of a compound modulating kinases
CN112119072A (zh) 2018-03-20 2020-12-22 普莱希科公司 用于ido和tdo调节的化合物和方法，以及其适应症
EP3953351A1 (en) 2019-04-09 2022-02-16 Plexxikon Inc. Condensed azines for ep300 or cbp modulation and indications therefor
EP4139296A1 (en) 2020-04-23 2023-03-01 Opna Immuno Oncology, SA Compounds and methods for cd73 modulation and indications therefor
WO2022040512A1 (en) 2020-08-21 2022-02-24 Plexxikon Inc. Combinational drug anticancer therapies
CN115504925B (zh) * 2021-06-22 2024-03-12 广东药科大学 一类ppar激动剂、其制备方法及其作为药物的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466689A (en) * 1993-02-08 1995-11-14 Takeda Chemical Industries, Ltd. Morpholine derivatives and their use

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB957990A (en) * 1961-03-14 1964-05-13 Merck & Co Inc Salts of substituted indoles
FR1482844A (fr) 1964-12-31 1967-06-02 Merck & Co Inc Procédé de préparation de nouveaux acides 2-[2-(phénylalkyl substitué)-3-indolyl] aliphatiques inférieurs
US3489767A (en) * 1966-01-12 1970-01-13 Sumitomo Chemical Co 1-(phenylsulfonyl)-3-indolyl aliphatic acid derivatives
US3511841A (en) * 1967-05-29 1970-05-12 Sterling Drug Inc 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines
GB1573212A (en) * 1976-04-15 1980-08-20 Technicon Instr Immunoassay for gentamicin
US4568649A (en) * 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4626513A (en) * 1983-11-10 1986-12-02 Massachusetts General Hospital Method and apparatus for ligand detection
ATE56096T1 (de) 1984-03-15 1990-09-15 Immunex Corp Test zur sofortigen feststellung von liganden, testsatz und seine herstellung.
US5688655A (en) * 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
GB9004301D0 (en) * 1990-02-26 1990-04-18 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
US5283251A (en) * 1990-02-26 1994-02-01 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
US5075313A (en) * 1990-09-13 1991-12-24 Eli Lilly And Company 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
DE69434998T2 (de) * 1993-05-27 2008-03-13 Aventis Pharmaceuticals Inc. Topologisch getrennte, kodierende Festphasen-Bibliotheken
US5840485A (en) * 1993-05-27 1998-11-24 Selectide Corporation Topologically segregated, encoded solid phase libraries
US5763198A (en) * 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
GB9416467D0 (en) * 1994-08-13 1994-10-05 Wellcome Found Compounds for use in medicine
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5747276A (en) * 1995-09-15 1998-05-05 The Scripps Research Institute Screening methods for the identification of novel antibiotics
US6294330B1 (en) * 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
EP0972071A4 (en) * 1997-03-07 2004-04-21 Tropix Inc TEST ARRANGEMENT FOR PROTEAS INHIBITORS
US6178384B1 (en) * 1997-09-29 2001-01-23 The Trustees Of Columbia University In The City Of New York Method and apparatus for selecting a molecule based on conformational free energy
IL136954A0 (en) * 1997-12-24 2001-06-14 Aventis Pharma Gmbh Indole derivatives as inhibitors of factor xa
NZ506260A (en) 1998-02-23 2003-05-30 Univ South Alabama Indole-3-propionic acids, salts and esters thereof used as medicaments
JP2000226373A (ja) * 1998-04-08 2000-08-15 Takeda Chem Ind Ltd アミン誘導体、その製造法および剤
WO1999052875A1 (en) * 1998-04-08 1999-10-21 Takeda Chemical Industries, Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
AU4543899A (en) * 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
WO2000029023A1 (en) * 1998-11-12 2000-05-25 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with nmda-blockers for treating pain
AU1398899A (en) * 1998-11-12 2000-06-05 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with centrally acting analgesics
EP1177187B1 (en) * 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
CZ20013834A3 (cs) 1999-04-28 2002-04-17 Aventis Pharma Deutschland Gmbh Deriváty kyselin se třemi arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují
AU778282B2 (en) 1999-09-17 2004-11-25 Kyorin Pharmaceutical Co. Ltd. O-anisamide derivatives
FR2801585B1 (fr) * 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
CA2699568C (en) 1999-12-24 2013-03-12 Aventis Pharma Limited Azaindoles
AU2001258838A1 (en) 2000-05-29 2001-12-11 Kyorin Pharmaceutical Co. Ltd. Substituted phenylpropionic acid derivatives
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
AU2001286259A1 (en) * 2000-09-22 2002-04-02 Shionogi And Co., Ltd. Tricyclic indole compounds having affinity for serotonin receptor
BR0114617A (pt) 2000-10-11 2005-12-13 Esperion Therapeutics Inc Composto, composição farmacêutica, métodos para tratar ou previnir uma doença cardiovascular, uma dislipidemia, uma dislipoproteinemia, um distúrbio do metabolismo da glicose, trombótico e associado com o receptor ativado do proliferador de peroxissoma, a doença de alzheimer, a sìndrome x ou sìndrome metabólica, a septicemia, a obesidade, pancreatite, a hipertensão, doença renal, câncer, a inflamação e a impotência, em um paciente e para reduzir o teor de gordura da carne em animal de criação e de colesterol de ovos de aves domésticas
CN100344616C (zh) * 2001-06-12 2007-10-24 维尔斯达医疗公司 用于治疗代谢失调的化合物
WO2003018553A1 (en) * 2001-08-29 2003-03-06 Warner-Lambert Company Llc Oral antidiabetic agents
US6806265B2 (en) * 2002-05-16 2004-10-19 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
AU2003281040A1 (en) 2002-07-10 2004-02-02 Sumitomo Pharmaceuticals Co., Ltd. Biaryl derivatives
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
EP1578716A1 (en) 2002-12-20 2005-09-28 Novo Nordisk A/S Dicarboxylic acid derivatives as ppar-agonists
EP1475094B8 (en) 2003-05-06 2011-01-12 Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO) Pyrazolo[4,3-D]pyrimidines, process for their preparation and methods of use
JP4845730B2 (ja) 2003-07-17 2011-12-28 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
US7348338B2 (en) 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
JPWO2005012221A1 (ja) 2003-08-04 2006-09-14 小野薬品工業株式会社 ジフェニルエーテル化合物、その製造方法および用途
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
JP2007508382A (ja) 2003-10-14 2007-04-05 イーライ リリー アンド カンパニー Ｐｐａｒモジュレータとしてのフェノキシエーテル誘導体
GB2407318A (en) * 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
GB0324886D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
ES2299906T3 (es) 2003-11-25 2008-06-01 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisomas.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466689A (en) * 1993-02-08 1995-11-14 Takeda Chemical Industries, Ltd. Morpholine derivatives and their use

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491831B2 (en) 2003-07-17 2009-02-17 Plexxikon, Inc. PPAR active compounds
US8367828B2 (en) 2003-07-17 2013-02-05 Plexxikon Inc. PPAR active compounds
US7723374B2 (en) 2003-07-17 2010-05-25 Plexxikon, Inc. PPAR active compounds
US7572806B2 (en) 2003-07-17 2009-08-11 Plexxikon, Inc. PPAR active compounds
US7476746B2 (en) 2003-07-17 2009-01-13 Plexxikon, Inc. PPAR active compounds
WO2006002125A1 (en) * 2004-06-23 2006-01-05 Wyeth Indolylalkylamine metabolites as 5-hydroxytrytamine-6 ligands
US7498327B2 (en) 2004-06-23 2009-03-03 Wyeth Indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands
US7531568B2 (en) 2004-11-30 2009-05-12 Plexxikon, Inc. PPAR active compounds
US7842692B2 (en) * 2005-07-22 2010-11-30 Shionogi & Co., Ltd. Azaindole derivative having PGD2 receptor antagonistic activity
KR101378637B1 (ko) 2005-08-30 2014-04-01 라보라뚜와르 푸르니에 에스.아. 신규한 인돌 화합물
EA013795B1 (ru) * 2005-08-30 2010-06-30 Лабораториз Фурнье С.А. Производные индола и их применение
JP2009506099A (ja) * 2005-08-30 2009-02-12 ラボラトワール フルニエ エス・アー 新規インドール化合物
FR2890071A1 (fr) * 2005-08-30 2007-03-02 Fournier Sa Sa Lab Nouveaux composes de l'indole
WO2007026097A1 (fr) * 2005-08-30 2007-03-08 Laboratoires Fournier S.A. Nouveaux composes de l'indole
US7795297B2 (en) 2005-08-30 2010-09-14 Laboratories Fournier S.A. Indole compounds, method of preparing them and uses thereof
NO340381B1 (no) * 2005-08-30 2017-04-10 Inventiva Indolderivater, fremgangsmåte for fremstilling av slike, farmasøytiske preparater omfattende slike, anvendelse av slike som farmakologisk aktiv substans og anvendelse av slike for fremstilling av medikament for behandling av sykdom
EA014185B1 (ru) * 2005-09-01 2010-10-29 Лабораториз Фурнье С.А. Производные пирролопиридина и их применение в качестве модуляторов ppar-рецепторов
US7728002B2 (en) 2005-09-01 2010-06-01 Laboratoires Fournier S.A. Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors
AU2006286348B2 (en) * 2005-09-01 2012-04-26 Inventiva Pyrrolopyridine derivatives and use of same as PPAR receptor modulators
WO2007026104A1 (fr) * 2005-09-01 2007-03-08 Laboratoires Fournier S.A. Derives de pyrrolopyridine et leurs utilisations comme modulateurs des recepteurs ppar
US7557122B2 (en) 2005-09-01 2009-07-07 Laboratoires Fournier S.A. Pyrrolopyridine compounds, method of making them and uses thereof
NO340681B1 (no) * 2005-09-01 2017-05-29 Inventiva Pyrrolopyridinderivater, framgangsmåte for fremstilling, farmasøytisk praparater omfattende slike, slike forbindelser som farmakologisk aktive substanser samt anvendelse av slike forbindelser og preparater for behandling av sykdom
CN101242833B (zh) * 2005-09-01 2012-06-27 实验室富尼耶公司 吡咯并吡啶衍生物及其作为ppar受体调控剂的用途
WO2007030559A2 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1, 3-disubstituted indole derivatives for use as ppar modulators
WO2007030559A3 (en) * 2005-09-07 2007-09-13 Plexxikon Inc 1, 3-disubstituted indole derivatives for use as ppar modulators
JP2009507079A (ja) * 2005-09-07 2009-02-19 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
US7855225B2 (en) 2006-03-02 2010-12-21 Astellas Pharma Inc. 17βHSD type 5 inhibitor
JP2010520877A (ja) * 2007-03-08 2010-06-17 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
WO2008109700A1 (en) * 2007-03-08 2008-09-12 Plexxikon, Inc. Ppar active compounds
US8053463B2 (en) 2007-03-08 2011-11-08 Plexxikon Inc. PPAR active compounds
US8420666B2 (en) 2007-03-14 2013-04-16 Ranbaxy Laboratories Limited Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors
CN102149712A (zh) * 2008-02-29 2011-08-10 阵列生物制药公司 吡唑并[3，4-b]吡啶Raf抑制剂
WO2009111279A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Pyrazole [3, 4-b] pyridine raf inhibitors
US8394795B2 (en) 2008-02-29 2013-03-12 Array Biopharma Inc. Pyrazole [3, 4-B] pyridine Raf inhibitors
WO2010106076A1 (fr) 2009-03-16 2010-09-23 Laboratoires Arkopharma STIMULATEUR MÉTABOLIQUE DES PPARs À BASE D'ESTERS D'ACIDES GRAS LIBRES INSATURÉS, COMPOSITION HUILEUSE ET COMPLÉMENT ALIMENTAIRE LES CONTENANT
WO2010127246A3 (en) * 2009-04-30 2010-12-29 Burnham Institute For Medical Research Hnf4 modulators and methods of use
WO2010127264A3 (en) * 2009-04-30 2010-12-23 Burnham Institute For Medical Research HNF4α ANTAGONISTS AND METHODS OF USE
US8546385B2 (en) 2010-01-08 2013-10-01 Laboratoires Fournier Sa Benzoic pyrrolopyridine derivatives
WO2011083278A1 (fr) 2010-01-08 2011-07-14 Laboratoires Fournier Sa Nouveaux derives de type pyrrolopyridine benzoique
WO2011086307A1 (fr) 2010-01-08 2011-07-21 Laboratoires Fournier S.A. Dérivés de pyrrolopyridine comme activateurs de nurr-1 utiles pour le traitement de la maladie de parkinson
WO2012178142A1 (en) * 2011-06-23 2012-12-27 Metabolic Solutions Development Company, Llc Ppar-sparing compounds and combinations fort the treatment of diabetes and other metabolic diseases
US11738004B2 (en) 2011-10-17 2023-08-29 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
WO2013169864A2 (en) 2012-05-08 2013-11-14 Lycera Corporation TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
EP2847198A4 (en) * 2012-05-08 2015-11-25 Lycera Corp TETRAHYDRO [1,8] NAPHTHYRIDINE-SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS MMR AGONISTS AND IN THE TREATMENT OF DISEASE
AU2013259624B2 (en) * 2012-05-08 2017-10-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
WO2015050412A1 (en) * 2013-10-02 2015-04-09 Daewoong Pharmaceutical Co., Ltd. Sulfonylindole derivatives and method for preparing the same
CN105612150A (zh) * 2013-10-02 2016-05-25 株式会社大熊制药 磺酰吲哚衍生物和制备该磺酰吲哚衍生物的方法
US9676714B2 (en) 2013-10-02 2017-06-13 Daewoong Pharmaceutical Co., Ltd. Sulfonylindole derivatives and method for preparing the same
CN105612150B (zh) * 2013-10-02 2018-04-10 株式会社大熊制药 磺酰吲哚衍生物和制备该磺酰吲哚衍生物的方法
WO2018033455A1 (de) 2016-08-15 2018-02-22 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel

Also Published As

Publication number Publication date
JP4845730B2 (ja) 2011-12-28
KR20130023381A (ko) 2013-03-07
US20070155818A1 (en) 2007-07-05
US20080045581A1 (en) 2008-02-21
EP1648867A4 (en) 2008-07-23
US20050038246A1 (en) 2005-02-17
KR20060112710A (ko) 2006-11-01
EP1648867B1 (en) 2013-09-04
IL173079A0 (en) 2006-06-11
HK1086010A1 (en) 2006-09-08
RU2006100920A (ru) 2007-08-27
ECSP066288A (es) 2006-07-28
BRPI0412684A (pt) 2006-10-03
CA2532403A1 (en) 2005-02-03
CN102875441A (zh) 2013-01-16
UA88767C2 (uk) 2009-11-25
US7476746B2 (en) 2009-01-13
AU2004259738B2 (en) 2011-11-17
EP1648867A1 (en) 2006-04-26
US20070149603A1 (en) 2007-06-28
RU2356889C2 (ru) 2009-05-27
NZ545326A (en) 2009-12-24
DK1648867T3 (da) 2013-12-16
US7723374B2 (en) 2010-05-25
CR8194A (es) 2007-01-18
US8367828B2 (en) 2013-02-05
US20100210036A1 (en) 2010-08-19
KR101415503B1 (ko) 2014-07-04
IL173079A (en) 2011-09-27
JP2007534625A (ja) 2007-11-29
AU2004259738A1 (en) 2005-02-03
NO20060385L (no) 2006-02-16
US7491831B2 (en) 2009-02-17
US7202266B2 (en) 2007-04-10

Similar Documents

Publication Publication Date Title
AU2004259738B2 (en) PPAR active compounds
US7348338B2 (en) PPAR active compounds
CA2550361C (en) Compounds and methods for development of ret modulators
US20070066641A1 (en) Compounds and methods for development of RET modulators
US7605168B2 (en) PDE4B inhibitors
Mahboobi et al. Bis (1 H-2-indolyl) methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase
EP1755597A2 (en) Azaindoles modulating c-kit activity and uses therefor
MXPA01012795A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir a las proteinas cinasas, y metodos para su uso.
Lingam et al. Design, Synthesis, and Pharmacological Evaluation of 5, 6-Disubstituted Pyridin-2 (1 H)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists
MXPA06000624A (en) Ppar active compounds
TW200536527A (en) PPAR active compounds
Guo Hot Spot-Based Design and Synthesis of Small Molecule Inhibitors for β-Catenin/T-Cell Factor 4 Protein-Protein Interaction and Hemiporphyrin-Like N2-Acyl 2-Aminoimidazoles: Chemistry, Biology and Zinc Binding Properties
CN1845898A (zh) Ppar活性化合物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480025050.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2532403

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006/00435

Country of ref document: ZA

Ref document number: 06003175

Country of ref document: CO

Ref document number: 200600435

Country of ref document: ZA

Ref document number: 1020067001015

Country of ref document: KR

Ref document number: PA/a/2006/000624

Country of ref document: MX

Ref document number: 12006500136

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2006520413

Country of ref document: JP

Ref document number: CR2006-008194

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 262/KOLNP/2006

Country of ref document: IN

Ref document number: 2004259738

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004778641

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 545326

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1200600241

Country of ref document: VN

Ref document number: 2006100920

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2004259738

Country of ref document: AU

Date of ref document: 20040716

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004259738

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004778641

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0412684

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 1020067001015

Country of ref document: KR